Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series.

Tobias JanowitzEva GablenzDavid PattinsonTimothy C WangJoseph ConigliaroKevin TraceyDavid A Tuveson

Published in: Gut (2020)

The results of this case series suggest that high-dose oral famotidine is well tolerated and associated with improved patient-reported outcomes in non-hospitalised patients with COVID-19.

Keyphrases

patient reported outcomes
high dose
end stage renal disease
coronavirus disease
sars cov
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
low dose
high resolution